Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: Clinical and in vitro evidence

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 703-711

  Teo, Yi Ling ^a   Saetaew, Manit ^b   Chanthawong, Suthan ^c   Yap, Yoon Sim ^d   Yong Chan, Eric Chun ^a   Ho, Han Kiat ^a   Chan, Alexandre ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UBON RATCHATHANI UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Cell viability; CYP3A4; Dexamethasone; Drug drug interaction; Hepatotoxicity; Lapatinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; AROMATASE INHIBITOR; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CYTOCHROME P450 3A4; DEXAMETHASONE; LAPATINIB; NAVELBINE; TAMOXIFEN; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; VINCA ALKALOID;

ADULT; ANIMAL CELL; ARTICLE; BREAST CANCER; CASE CONTROL STUDY; CELL CULTURE; CELL VIABILITY; CLINICAL STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; IN VITRO STUDY; INCIDENCE; LIVER CELL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84983727007     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1995-7     Document Type: Article

References (37)

1. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL (2002) Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263. doi:10.1038/sj.onc.1205794
2. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pien-kowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743. doi:10.1056/NEJMoa064320
3. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538-5546. doi:10.1200/JCO.2009.23.3734
4. Gomez HL, Doval DC, Chavez MA, Ang PCS, Aziz Z, Nag S, Ng C, Franco SX, Chow LWC, Arbushites MC, Casey MA, Berger MS, Stein SH, SledgeGW (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or meta-static breast cancer. J Clin Oncol 26:2999-3005. doi:10.1200/JCO.2007.14.0590
5. Duckett DR, Cameron MD (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol 6:1175-1193. doi:10.1517/17425255.2010.506873
6. GlaxoSmithKline (ed) (2011) Tykerb Prescribing Information
7. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan ECY (2010) Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78:693-703. doi: 10.1124/mol.110.065839
8. Ju C, Uetrecht JP (2002) Mechanism of idiosyncratic drug reactions: reactive metabolites formation, protein binding and the regulation of the immune system. Curr Drug Metab 3:367-377. doi:10.2174/1389200023337333
9. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17:4834-4843. doi:10.1158/1078-0432.CCR-10-2962
10. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278-5286. doi:10.1200/JCO.2008. 19.8481
11. Chang EL, Lo S (2003) Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 8:398-410. doi:10.1634/theoncologist. 8-5-398
12. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Kalkanis SN (2010) The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neu-rooncol 96:103-114. doi:10.1007/s11060-009-0057-4
13. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van Den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999. doi:10.1200/JCO.2007.12. 3588
14. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459. doi:10.1158/1078-0432.CCR-08-1080
15. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-a expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58:361-372
16. Micromedex® 2.0 (2011) Thomson Reuters (Healthcare). Accessed Oct 2011
17. Lexi-Comp (2011) Lexi-Comp Inc. Accessed Oct 2011
18. Navarro VJ, Senior JR (2006) Drug-related hepatotoxicity. N Engl J Med 354:731-739. doi:10.1056/NEJMra052270
19. Wu JC, Merlino G, Cveklova K, Mosinger B Jr, Fausto N (1994) Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor a. Cancer Res 54: 5964-5973
20. Martignoni M, De Kanter R, Grossi P, Saturno G, Barbaria E, Monshouwer M (2006) An in vivo and in vitro comparison of CYP gene induction in mice using liver slices and quantitative RT-PCR. Toxicol In Vitro 20:125-131. doi:10.1016/j.tiv.2005. 06.040
21. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
22. Sylvester PW (2011) Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 716:157-168
23. Vermeir M, Annaert P, Mamidi RNVS, Roymans D, Meulder-mans W, Mannens G (2005) Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1:75-90. doi:10.1517/17425255.1.1.75
24. Pierce RH, Franklin CC, Campbell JS, Tonge RP, Chen W, Fausto N, Nelson SD, Bruschi SA (2002) Cell culture model for acetaminophen-induced hepatocyte death in vivo. Biochem Pharmacol 64:413-424. doi:10.1016/S0006-2952(02)01180-2
25. Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ (2010) Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol 75:110-121. doi: 10.1016/j.critrevonc.2009.11.003
26. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322. doi: 10.2174/ 138920008784220664
27. Srivastava A, Maggs JL, Antoine DJ, Williams DP, Smith DA, Park BK (2010) Role of reactive metabolites in drug-induced hepatotoxicity. In: Uetrecht J (ed) Adverse drug reactions, Handbook of experimental pharmacology, 1st edn. Springer-Verlag, Heidelberg, pp 165-194
28. Dahlin DC, Miwa GT, Lu AY, Nelson SD (1984) N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. ProcNatl Acad Sci USA 81:1327-1331
29. Guo GL, Moffit JS, Nicol CJ, Ward JM, Aleksunes LA, Slitt AL, Kliewer SA, Manautou JE, Gonzalez FJ (2004) Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol Sci 82:374-380. doi:10.1093/toxsci/kfh286
30. Blower P, De Wit R, Goodin S, Aapro M (2005) Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 55:117-142. doi: 10.1016/j.critrevonc.2005.03.007
31. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC (2008) Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 5:268-278. doi: 10.1038/ncponc1087
32. Asnacios A, Naveau S, Perlemuter G (2009) Gastrointestinal toxicities of novel agents in cancer therapy. Eur J Cancer 45:332-342. doi:10.1016/S0959- 8049(09)70047-4
33. Demirci U, Buyukberber S, Yilmaz G, Kerem M, Coskun U, Uner A, Baykara M, Pasali H, Benekli M (2011) Hepatotoxicity associated with lapatinib in an experimental rat model. Eur J Cancer 48(2):279-285. doi:10.1016/j.ejca.2011.10. 011
34. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR (2011) HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29:667-673
35. Andrade RJ, Camargo R, Lucena MI, González-Grande R (2004) Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 3:329-344. doi:10.1517/14740338.3.4.329
36. Senior JR (2009) Monitoring for hepatotoxicity: what is the predictive value of liver ''function'' tests? Clin Pharmacol Ther 85:331-334. doi:10.1038/clpt.2008.262
37. Lee WM, Senior JR (2005) Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 33:155-164. doi:10.1080/ 01926230590522356